Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FELICIA trial of medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma
jRCT2031190065Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of metformin and medroxyprogesterone acetate in Endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Three-year disease-free survival rate. Started Sep 2019; status: completed.
02
Drugs
metforminmedroxyprogesterone acetate
03
Conditions
Endometrial intraepithelial neoplasia (EIN)endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031190065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190065.